Midwest Medication Safety Symposium (M2S2) Lunch & Learn Webinar- ICPS COVID Pearls

The Midwest Medication Safety Symposium (M2S2) Lunch & Learns are fourteen one-hour virtual interdisciplinary meetings created to provide an opportunity for health-care providers to collaborate and learn new medication safety strategies. Each Lunch & Learns focuses on improving medication safety practices and patient outcomes through education of pharmacists and interprofessional health care teams and is recorded for future viewing.

This video is the recorded presentation from the live session on March 9, 2021. 

Launch Date: 4/14/2021

Expiration Date: 4/14/2022

How to obtain CE credits:

Please note, you have to watch the entire video in order to receive any CE credit for this online activity.

Sign in or create a new account by clicking "Sign In" in top left corner. *If you previously participated in a CME activity accredited by IUSM  but do not know your password, please enter your email address and click on the 'Forget Your Password' link. Your password will be emailed to you.

1. Click the Tests tile > Launch Video to view the module.
2. After viewing the video go back to the Tests tile and click Post-Test to attest to completing the activity.
3. Click the MyCME button > Evaluations and Certificates
4. Find the activity name in the list and click Complete Evaluation.
5. Click Submit.
6. On the Evaluations and Certificates page, click Download Certificate or access your transcript through the Transcript tile.
   

1. Explain medication safety terminology and methodology for frontline staff, students, new and established practitioners as well as direct and non-direct patient caregivers;
2. Recognize the importance and be able to incorporate an interdisciplinary approach to medication safety; and
3. Review opportunities to improve medication safety through the use of technology, process improvement, and implementing innovative or evidence based best practices.

References:

1. Pre-print. Thromboelastography-Guided Management of Anticoagulated COVID-19 Patients to Prevent Hemorrhage. Semin Thromb Hemost 2021. In Press.
2. Pre-print. Thromboelastography-Guided Anticoagulant Therapy for the Double Hazard of Thrombohemorrhagic Events in COVID-19: A Report of Three Cases. Am J Case Rep. 2021. In Press.
3. Evans P et al. Endothelial dysfunction in COVID-19: a position paper of the ESC Working Group for Atherosclerosis and Vascular Biology. Cardiovascular Research.  Doi: 10.1093/cvr/cvaa230
4. Park BM et al. Coagulopathy in COVID-19: Review and Recommendations, U of Miami, Div Trauma Surg & Surg Crit Care.
5. NIH Guidance / Wendling. Medscape 2021 Jan 22. Full-Dose Anticoagulation Reduces Need for Life Support in COVID-19
6. Xiang-Hua et al. Am J Respir Crit Care Med, 182 (3), 436-7. PMID: 20675682
7. Tang et al. J Thromb Haemost 2020 Mar 27. PMID: 32220112
8. Belouzard et al. Proc Natl Acad Sci, 2009 106 (14), 5871-6. PMID: 19321428
9. Kotz. UM School of Medicine New Landmark Study; ASA Reduces Risk of Death 2020 Oct 22
10. Spyropoulos AC, et al. Emergence of Institutional Antithrombotic Protocols for Coronavirus 2019. doi: 10.1002/rth2.12358
11. Loyola University Medical Center, Hematology/Oncology and  Michiana Hematology/Oncology, Mishawaka, IN
12. Hartmann J et al. The Role of TEG Analysis in Patients with COVID-19-Associated Coagulopathy: A Systematic Review. Diagnostics 2021, 11, 172.
13. Brubaker L et al. Thomboelastography Might Be More Applicable to Guide Anticoagulant Therapy than Fibrinolytic Therapy in Critically Ill Patients with COVID-19. J Am Coll Surg. 2021 Feb; 232(2):227-229.
14. 2020 National Patient Safety Goals. The Joint Commission. July 2020. Accessed January 29, 2021. https://www.jointcommission.org/standards/national-patient-safety-goals/-/media/c27cb0eca3154375a6da1ec2a7ed4c6f.ashx
15. Adams KK, Baker WL, Sobieraj DM. Myth Busters: Dietary Supplements and COVID-19. Ann Pharmacother. 2020;54(8):820-826. doi:10.1177/1060028020928052
16. Advancing patient-provider communication and activating patients. The Joint Commission Quick Safety. Issue 29. November 2016. Accessed January 29, 2021. https://www.jointcommission.org/-/media/tjc/documents/newsletters/quick_safety_issue_29_nov_2016pdf.pdf
17. Bull-Otterson L, Gray EB, Budnitz DS, et al. Hydroxychloroquine and Chloroquine Prescribing Patterns by Provider Specialty Following Initial Reports of Potential Benefit for COVID-19 Treatment - United States, January-June 2020. MMWR Morb Mortal Wkly Rep. 2020;69(35):1210-1215. Published 2020 Sep 4. doi:10.15585/mmwr.mm6935a4
18. Call for Action: Managing the Infodemic. World Health Organization. Accessed January 25, 2021. https://www.who.int/news/item/11-12-2020-call-for-action-managing-the-infodemic
19. Chan MS, Jones CR, Hall Jamieson K, Albarracín D. Debunking: A Meta-Analysis of the Psychological Efficacy of Messages Countering Misinformation. Psychol Sci. 2017;28(11):1531-1546. doi:10.1177/0956797617714579
20. Emani VR, Goswami S, Nandanoor D, Emani SR, Reddy NK, Reddy R. Randomised controlled trials for COVID-19: evaluation of optimal randomisation methodologies-need for data validation of the completed trials and to improve ongoing and future randomised trial designs. Int J Antimicrob Agents. 2021;57(1):106222. doi:10.1016/j.ijantimicag.2020.106222
21. Gupta L, Gasparyan AY, Misra DP, Agarwal V, Zimba O, Yessirkepov M. Information and Misinformation on COVID-19: a Cross-Sectional Survey Study. J Korean Med Sci. 2020;35(27):e256. Published 2020 Jul 13. doi:10.3346/jkms.2020.35.e256
22. Hydroxychloroquine (Plaquenil) Shortage Causing Concern. Arthritis Foundation. Updated March 24, 2020. Accessed January 25, 2020. https://www.arthritis.org/drug-guide/medication-topics/plaquenil-shortage#:~:text=Hydroxychloroquine%20(Plaquenil)%20Shortage%20Causing%20Concern%20Possible%20use%20of,arthritis.%20Updated%20March%202%204%20,%202020%20%E2%80%93
23. Iyengar S, Massey DS. Scientific communication in a post-truth society. Proc Natl Acad Sci U S A. 2019;116(16):7656-7661. doi:10.1073/pnas.1805868115
24. Kelly M, O'Connor R, Townsend L, et al. Clinical outcomes and adverse events in patients hospitalised with COVID-19, treated with off-label hydroxychloroquine and azithromycin [published online ahead of print, 2020 Jul 20]. Br J Clin Pharmacol. 2020;10.1111/bcp.14482.
25. Let’s Flatten the Infodemic Curve. World Health Organization. Accessed on January 26, 2021. https://www.who.int/news-room/spotlight/let-s-flatten-the-infodemic-curve
26. Merchant RM, Asch DA. Protecting the Value of Medical Science in the Age of Social Media and “Fake News”. JAMA. 2018;320(23):2415–2416. doi:10.1001/jama.2018.18416
27. Merchant RM, South EC, Lurie N. Public Health Messaging in an Era of Social Media. JAMA. 2021;325(3):223–224. doi:10.1001/jama.2020.24514
28. Mheidly N, Fares J. Leveraging media and health communication strategies to overcome the COVID-19 infodemic. J Public Health Policy. 2020 Dec;41(4):410-420. doi: 10.1057/s41271-020-00247-w. PMID: 32826935; PMCID: PMC7441141.
29. Rosenberg ES, Dufort EM, Udo T, et al. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. JAMA. 2020;323(24):2493-2502. doi:10.1001/jama.2020.8630
30. Vermeir P, Vandijck D, Degroote S, et al. Communication in healthcare: a narrative review of the literature and practical recommendations. Int J Clin Pract. 2015;69(11):1257-1267. doi:10.1111/ijcp.12686